Compare Inovio Pharmaceuticals Inc (INO) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vertiv Holdings Co — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Vertiv Holdings Co trades at $301.5 (market cap $112.03B). The key difference: Vertiv Holdings Co is far larger — about 1255× Inovio Pharmaceuticals Inc's market cap, and Vertiv Holdings Co pays a 0.09% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | VRT | |
|---|---|---|
Market Cap | $89.27M | $112.03B |
Sector | Health | Technology |
52-Week High | $2.87 | $376.23 |
52-Week Low | $1.05 | $121.82 |
Enterprise Value | $60.28M | $112.80B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Vertiv Holdings (VRT) trades at $291.67, up 0.73% with strong analyst support (94.7% buy ratings) and a $402.92 consensus price target. The stock shows bearish technical signals but maintains robust fundamentals with 14.37% net margins and consistent earnings beats. Recent news highlights AI infrastructure demand driving Vertiv's $15 billion backlog and expansion in Malaysia to support growth.
Outlook remains positive given AI-driven data center investments, though premium valuations (P/E 72.75) and technical weakness near support at $282 pose near-term risks. Earnings on July 29 will be critical for confirming growth trajectory amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
